Endogenous Growth Factors
Naturally produced by cells and tissues as part of normal development, repair, immune regulation and physiological signalling.
CELLMEX Scientific Library
Growth Factors
Growth factors are biologically active signalling proteins that bind specific cellular receptors and regulate proliferation, survival, migration, differentiation, tissue organisation and repair. They are central to cellular biology, laboratory culture systems and several established medical therapies.
Scientific Definition
What exactly is a growth factor?
Growth factors are naturally occurring proteins or polypeptides that transmit biological instructions between cells and their surrounding tissues.
A growth factor normally acts by binding to a specific receptor on the surface of a target cell. Receptor activation initiates intracellular signalling pathways that may change gene expression, metabolism, cell-cycle activity, survival or differentiation.
Despite their name, growth factors do more than increase cell number. Depending on the factor, concentration, timing and cellular context, they may promote proliferation, maintain immaturity, induce differentiation, support migration or suppress selected cellular responses.
Recombinant Growth Factors
Manufactured through controlled biotechnology processes to produce a defined protein for laboratory, research or medicinal use.
Secretome-Associated Growth Factors
Growth factors released by cultured cells into conditioned medium or carried within or alongside extracellular-vesicle preparations.
Growth-Factor Biology
From receptor binding to cellular response
Biological activity depends on the target cell, receptor expression, dose, duration of exposure and interaction with other signalling molecules.
Factor Availability
A growth factor is produced naturally or introduced into a controlled culture or treatment system.
Receptor Binding
The factor binds a compatible receptor expressed by the target cell.
Signal Activation
Receptor activation initiates intracellular signalling pathways.
Gene Regulation
Cellular transcription, protein production and metabolism may change.
Biological Response
The cell may proliferate, migrate, survive, differentiate or alter its secretory activity.
Concentration Matters
Low and high concentrations of the same factor may produce different cellular responses. Excessive exposure may cause receptor desensitisation, abnormal proliferation or loss of the intended phenotype.
Timing Matters
Continuous exposure, short pulses and sequential exposure may produce different effects during cell expansion or differentiation.
Cellular Context Matters
A factor may stimulate one cell type while having little effect or a different effect on another cell population.
Combined Signalling Matters
Growth factors frequently operate in networks. Combinations may act additively, synergistically or antagonistically.
Major Growth-Factor Families
Different factors regulate different biological systems
The following examples are frequently encountered in cellular research, regenerative biology and biomanufacturing.
Fibroblast Growth Factors
FGF-family proteins participate in proliferation, development, angiogenesis, wound biology and maintenance of selected stem-cell cultures.
Basic FGF, also known as FGF2, is frequently used during MSC and pluripotent-cell culture.
Transforming Growth Factor Beta
TGF-β-family signalling influences immune regulation, matrix biology, fibrosis and differentiation.
Defined TGF-β exposure is commonly used in chondrogenic differentiation protocols.
Platelet-Derived Growth Factors
PDGF-family proteins influence migration, proliferation and survival of stromal, vascular and connective-tissue-associated cells.
Vascular Endothelial Growth Factors
VEGF-family signalling is central to vascular development, endothelial-cell activity and angiogenesis.
Epidermal Growth Factor
EGF signalling influences epithelial-cell proliferation, survival and tissue-repair responses.
Insulin-Like Growth Factors
IGF-family signalling contributes to growth, metabolism, survival and musculoskeletal tissue biology.
Bone Morphogenetic Proteins
BMP-family proteins belong to the TGF-β superfamily and regulate bone formation, development and lineage-associated differentiation.
Hepatocyte Growth Factor
HGF participates in cellular survival, migration, tissue repair and epithelial and vascular signalling.
Haematopoietic Growth Factors
Factors such as erythropoietin and granulocyte-colony stimulating factor regulate production and maturation of defined blood-cell lineages.
Cellular Production
How growth factors are used in stem-cell manufacturing
Growth factors can be critical raw materials because they influence cell yield, phenotype, differentiation, secretory behaviour and final-product consistency.
Cell Recovery and Initial Culture
Selected factors may support cellular survival, attachment or recovery after tissue isolation, thawing or transfer into culture.
Cellular Expansion
Factors such as FGF2 may be used to promote proliferation and increase cell yield during controlled expansion.
Maintenance of Cellular Phenotype
Defined signalling conditions may help preserve selected cellular characteristics while limiting unwanted spontaneous differentiation.
Lineage Induction
Specific combinations of factors may direct cells toward osteogenic, chondrogenic, vascular, neural-associated or other lineage-related phenotypes.
Controlled Maturation
Sequential changes in growth-factor exposure may support progressive maturation toward a defined cellular phenotype.
Cellular Priming
Growth factors or cytokines may be used to alter MSC immunological, trophic or secretory characteristics before product collection.
Secretome Modification
Exposure can change the quantity and composition of proteins, cytokines and extracellular vesicles released by cultured cells.
Final Removal or Control
Residual recombinant growth factor may require removal, measurement or defined acceptance limits in the final cellular or cell-free product.
Lineage-Directed Biology
Growth factors guide differentiation; they are not differentiated
Cellular differentiation involves changes in gene expression, metabolism, morphology and function. Growth factors may help initiate or reinforce these changes by activating selected signalling pathways.
A differentiation protocol usually combines growth factors with defined media, supplements, extracellular-matrix conditions, oxygen tension and a controlled maturation period.
The resulting cell population must be characterised. Exposure to a differentiation factor does not by itself prove that the cells achieved a mature, stable or clinically functional phenotype.
Exosome and EV Production
Growth factors may alter extracellular-vesicle output
Culture conditions influence the quantity, composition and functional properties of cell-derived extracellular vesicles.
Cell Proliferation
Factors that increase viable cell numbers may also increase total vesicle production, although higher yield does not automatically mean improved quality.
Cellular Phenotype
Growth-factor exposure may change the phenotype and metabolic state of the source cells, thereby changing vesicle composition.
Vesicle Cargo
Signalling conditions may alter vesicle-associated proteins, lipids, messenger RNA and regulatory RNA.
Secretory Activity
Cellular priming may modify both soluble secretome production and extracellular-vesicle release.
Functional Properties
Changes in source-cell culture may alter immunological, angiogenic or tissue-supporting activity of the resulting EV preparation.
Process Comparability
Adding, removing or changing a growth factor may constitute a meaningful manufacturing change that requires analytical comparison.
Established Medical Use
Certain growth factors are authorised medicines
Medical use is product-specific. An approved indication for one recombinant growth factor does not establish approval for other factors, formulations, doses or regenerative applications.
Haematopoietic Support
Colony-stimulating factors may be used to support selected white-blood-cell populations following chemotherapy, transplantation or other defined medical circumstances.
Red-Blood-Cell Production
Erythropoiesis-stimulating medicines may be used for selected forms of anaemia under defined prescribing conditions.
Bone Formation
Certain recombinant bone morphogenetic protein products have been authorised for specific orthopaedic or surgical indications and delivery systems.
Wound Management
Selected recombinant platelet-derived growth-factor products have been developed for defined wound-care indications under controlled prescribing conditions.
Tissue Repair and Surgery
Certain growth-factor-based products may be used with specific scaffolds, carriers or surgical procedures rather than as general injectable regenerative medicines.
Recombinant Manufacture
Authorised growth-factor medicines are manufactured as controlled pharmaceutical or biological products with defined identity, strength, purity, stability and clinical indications.
Approved use is narrow and product-specific
The fact that a growth factor has an authorised use in haematology, surgery or wound care does not mean it is approved for stem-cell enhancement, anti-ageing, neurological disease, joint injections or cosmetic regeneration.
Potential Uses and Indications
Principal areas of regenerative research
These categories describe research and development areas. They do not establish that a growth-factor treatment is approved, clinically effective or appropriate for an individual patient.
Cartilage and Joint Biology
Growth factors are studied for their effects on chondrocytes, MSC differentiation, cartilage matrix production and inflammatory joint environments.
Bone Regeneration
Research examines osteogenic signalling, biomaterials, scaffolds and controlled local delivery for selected bone defects.
Tendon and Ligament Repair
Selected factors are studied for their effects on tendon-associated cells, matrix organisation and mechanical-tissue repair.
Wound and Skin Biology
Research includes epithelial repair, fibroblast activity, angiogenesis, matrix production and hair-follicle biology.
Neurological Research
Neurotrophic factors are studied for neuronal survival, neural repair, inflammation and specialised delivery systems.
Cardiovascular and Vascular Repair
Angiogenic and cytoprotective factors are studied in vascular disease, ischaemia and cardiac-injury models.
Ocular Disease
Growth-factor signalling is studied in corneal, retinal and vascular eye disorders, with effects varying according to the specific pathway.
Stem-Cell Priming
Growth factors may be used to modify MSC function or secretory activity before harvesting cells, conditioned medium or extracellular vesicles.
Controlled-Release Systems
Hydrogels, scaffolds, nanoparticles and extracellular-vesicle systems are studied to localise growth factors and control their release.
Manufacturing and Product Development
Patient-specific protocol or standardised product?
Growth factors themselves are normally produced as standardised recombinant or purified batches. Their use within a cellular programme may nevertheless be adapted to an individual patient or manufacturing protocol.
Patient-Specific Cellular Programme
A named-patient cell-manufacturing protocol may use growth factors to expand, prime or differentiate an individually assigned cell population.
- Defined clinical and scientific rationale
- Patient-linked or assigned source cells
- Selected factor and concentration
- Defined exposure period
- Washout or residual-factor controls
- Batch-specific characterisation
Standardised Growth-Factor Product
Recombinant growth factors may be manufactured as laboratory reagents, ancillary materials or medicinal products for broader controlled use.
- Defined molecular identity
- Controlled recombinant production
- Purity and biological-activity specifications
- Standardised vial or formulation
- Stability and distribution controls
- Product-specific regulatory classification
Growth factors are not normally individually manufactured
The protein reagent is usually produced in a standardised batch. What may be personalised is the selection, concentration, timing and use of that factor within an individual cellular or tissue-engineering protocol.
Personalised use does not remove the need for validated raw materials, manufacturing controls, clinical evidence, ethical review or applicable regulatory authorisation.
Quality and Manufacturing Control
Growth factors are critical process variables
Product name or stated concentration alone is insufficient. Identity, purity, biological activity, stability and residual exposure must be controlled.
Molecular Identity
Confirm the intended protein, sequence, isoform and relevant structural characteristics.
Purity
Evaluate aggregates, fragments, host-cell proteins, process contaminants and other impurities.
Biological Activity
Use an appropriate assay to confirm receptor-related activity or the intended cellular response.
Concentration and Dose
Control the amount added to culture or administered through a medicinal product.
Endotoxin and Microbiological Quality
Assess contamination risks appropriate to the factor's manufacturing process and intended use.
Stability
Define storage temperature, reconstitution, handling time and sensitivity to repeated freeze–thaw exposure.
Raw-Material Grade
Research-grade, animal-component-free, GMP-compatible and medicinal-product materials are not automatically interchangeable.
Cellular Comparability
Changes in supplier, formulation or concentration may alter cell growth, phenotype, differentiation or EV production.
Residual Growth Factor
Residual recombinant protein in the final product may require defined limits, removal or analytical assessment.
Clinical and scientific qualification
Growth factors are signalling proteins—not stem cells, exosomes, extracellular vesicles or differentiated tissues.
Their inclusion in a stem-cell culture or extracellular-vesicle manufacturing process may change the resulting cellular or cell-free product and must be documented as part of the manufacturing history.
A growth factor that is authorised for one specific medical indication should not be assumed to be safe or effective for another disease, route, dose or formulation.
Uncontrolled growth signalling may produce unwanted proliferation, fibrosis, vascular changes, inflammation or other biological effects. Growth factors should therefore not be promoted as universal regenerative, anti-ageing or tissue-restoration treatments.
Experimental growth-factor combinations require product-specific scientific evidence, appropriate clinical governance and jurisdiction-specific regulatory assessment.
The CELLMEX Approach
Controlled signalling within a defined biological process
Define the Scientific Objective
Determine whether the factor is intended for expansion, phenotype maintenance, priming, differentiation or secretome modification.
Select the Appropriate Material
Review source, grade, formulation, purity, biological activity and suitability for the manufacturing stage.
Control Concentration and Exposure
Define dose, timing, sequence, culture duration and removal or washout procedures.
Characterise the Cellular Response
Evaluate cell yield, morphology, phenotype, differentiation, senescence and functional activity.
Evaluate Secretome and EV Effects
Determine whether growth-factor exposure changes soluble-factor profiles, particle output, EV cargo or functional activity.
Separate Research from Clinical Use
Clearly distinguish laboratory optimisation, investigational treatment and authorised growth-factor medicinal products.
Selected Scientific References
Growth factors in cellular and extracellular-vesicle biology
Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell-secreted factors.
Journal of Translational Medicine. 2014;12:260.
View publicationImportance of stem-cell culture conditions for derived extracellular-vesicle production and therapeutic potential.
Review of culture parameters capable of modifying stem-cell-derived EV characteristics.
View publicationThermostable basic fibroblast growth factor enhances MSC proliferation and extracellular-vesicle production.
Experimental study examining FGF2 effects on Wharton's-jelly MSC culture and EV output.
View publicationPhinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy.
Review addressing exosome-associated cytokines, growth factors, lipids and regulatory nucleic acids.
View publicationStem cells: their source, potency and use in regenerative therapies.
Review discussing growth factors and other bioactive molecules involved in stem-cell paracrine activity.
View publicationCharacteristics of culture-condition-stimulated exosomes and their biological functions.
Review of hypoxia, three-dimensional culture, biochemical stimulation and other variables that alter source-cell and EV biology.
View publicationU.S. Food and Drug Administration. Important patient and consumer information about regenerative-medicine therapies.
Regulatory and patient-safety information concerning unapproved regenerative-medicine products.
View FDA informationEuropean Medicines Agency. Stem-cell-based medicinal products scientific guideline.
Quality, nonclinical and clinical considerations relevant to stem-cell-based medicinal-product development.
View EMA guidance
Scientific Information
Request information concerning CELLMEX growth-factor research
Physicians, researchers and institutions may request information concerning growth-factor use in cellular expansion, lineage-directed differentiation, secretome modification, extracellular-vesicle production and translational research.